RevMab

anti-p44 MAPK (Erk1), Rabbit Monoclonal (RM470)

CHF 459.00
In stock
REV-31-1362-00-R100100 µlCHF 459.00
More Information
Product Details
Synonyms Mitogen-activated protein kinase 3; MAPK3; MAP kinase isoform p44 (p44-MAPK); p44-Erk1
Product Type Recombinant Antibody
Properties
Clone RM470
Isotype Rabbit IgG
Source/Host Rabbit
Immunogen/Antigen A peptide corresponding to the C-terminus of human Erk1 (p44-MAPK).
Application

IHC: 1:100 - 1:200

WB: 1:1000 - 1:2000

Crossreactivity Human
Specificity

RM470 reacts to human Erk1 (p44-MAPK).

Purity Protein A purified.
Purity Detail Protein A affinity purified from an animal origin-free culture supernatant.
Formulation Liquid. 50% Glycerol/PBS with 1% BSA and 0.09% sodium azide.
Isotype Negative Control

Rabbit IgG

Other Product Data

Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.

Accession Number P27361
Declaration Manufactured by RevMab Biosciences.
Shipping and Handling
Shipping BLUE ICE
Long Term Storage -20°C
Handling Advice Avoid freeze/thaw cycles.
Use/Stability Stable for at least 1 year after receipt when stored at -20°C.
Documents
MSDS Inquire
Product Specification Sheet
Datasheet Download PDF
Description

Extracellular signal-regulated kinases 1 and 2 (also known as ERK1/2, p44/42, or MAPK3/1) belong to a family of conserved serine/threonine protein kinases known as mitogen-activated protein kinases (MAPKs) that are involved in many cellular programs such as proliferation, differentiation, motility and survival. The ERK1/2 signaling pathway can be activated in response to a diverse range of extracellular stimuli including mitogens, growth factors and cytokines. The primary activators of ERK1/2 are MEK1 and MEK2 which activate p44 and p42 through phosphorylation of activation loop residues Thr202/Tyr204 and Thr185/Tyr187 in ERK1 and ERK2, respectively. Several downstream targets of ERK1/2 have been identified, including p90RSK and the transcription factor Elk-1. ERK1/2 are negatively regulated by MAPK phosphatases as well as by chemical inhibitors of MEK. The ERK pathway is disrupted in many types of cancer and thus is an important target for diagnosis and treatment.

© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.